Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06391736
PHASE1/PHASE2

Evaluation of the Safety and Efficacy of Late-onset Pompe Disease Gene Therapy Drug

Sponsor: GeneCradle Inc

View on ClinicalTrials.gov

Summary

This study is being conducted to evaluate the safety and effectiveness of GC301 adeno-associated virus vector expressing codon-optimized human acid alpha-glucosidase (GAA) as potential gene therapy for Pompe disease. Patients diagnosed with late-onset Pompe disease (LOPD) who are ≥ 6 years old will be studied.

Official title: A Multi-centered, Single Arm, Open Labeled, Study to Evaluate the Safety, Tolerability, and Efficacy of an Adeno-associated Virus Vector Expressing the Human Acid Alpha-glucosidase (GAA) Transgene Intravenous Injection in Patients With Late-onset Pompe Disease

Key Details

Gender

All

Age Range

6 Years - Any

Study Type

INTERVENTIONAL

Enrollment

33

Start Date

2024-04-19

Completion Date

2026-12

Last Updated

2025-07-03

Healthy Volunteers

No

Interventions

GENETIC

GC301

GC301, is an adeno-associated virus 9 (AAV9) vector delivering a functional copy of the human GAA gene

Locations (1)

Chinese PLA General Hospital

Beijing, China